在急性髓性白血病中抑制 PI3Kγ。

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-07-24 DOI:10.1038/s43018-024-00791-4

Aaron J. Stonestrom, Ross L. Levine

引用次数: 0

摘要

磷脂酰肌醇-3-激酶-γ（PI3Kγ）的主要血液学表达特征使其成为一个有吸引力的治疗靶点。三个独立研究小组的最新研究表明，抑制 PI3Kγ 会影响急性髓性白血病细胞的新陈代谢和生长--这一发现为进一步的机理研究和临床探索提供了依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Inhibiting PI3Kγ in acute myeloid leukemia

查看原文本刊更多论文

Inhibiting PI3Kγ in acute myeloid leukemia

The mainly hematologic expression profile of phosphatidylinositol-3-kinase-γ (PI3Kγ) makes it an attractive therapeutic target. Recent work from three independent groups shows that inhibiting PI3Kγ impairs the metabolism and growth of acute myeloid leukemia cells — a finding that justifies further mechanistic and clinical exploration.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.